Jorge Esparza-Gordillo

Max Delbrück Center for Molecular Medicine Germany

Jorge Esparza-Gordillo obtained a BSc in Biology with specialty in Genetics at the Universidad Complutense de Madrid, Spain, followed by a PhD on Biochemistry and Molecular Genetics at the Center of Biological Research, Madrid, Spain. While preparing his PhD, he was involved in different research projects aiming to dissect the genetic and physiological basis of different autoimmune, thrombotic and metabolic human disorders. During this period, he gained knowledge of the immune system and the physiopathological mechanisms underlying complex disorders. Dr Esparza-Gordillo worked as a postdoctoral researcher at the “Max-Delbruck Center for molecular medicine” and at the “Charité - Universitätsmedizin Berlin” (Germany), where he was involved in research aiming to characterize the molecular mechanisms underlying Atopic Dermatitis and Asthma through genetic studies and analysis of data from population-based longitudinal cohorts.

Jorge Esparza-Gordillo

1books edited

Latest work with IntechOpen by Jorge Esparza-Gordillo

Atopic Dermatitis is a common disease characterized by inflamed, itching and dry skin. This relapsing allergic disorder has complex etiology and shows a remarkably high clinical heterogeneity which complicates the diagnosis and clinical management. This book is divided into 4 sections. The first section (Disease Etiology) describes some of the physiological mechanisms underlying Atopic Dermatitis, including alterations in the immune system and the skin-barrier function. The important role of host-microorganism interactions on the pathophysiology of Atopic Dermatitis is discussed in the second section (Microorganisms in Atopic Dermatitis). An overview of the clinical diagnostic criteria and the disease management protocols commonly used is given in the third section (Diagnosis and Clinical Management). The last section (New Treatments) describes new therapeutic approaches that are not widely used but are currently being studied due to preliminary evidence showing a clinical benefit for Atopic Dermatitis.

Go to the book